OA10697A - Injectable quinolone formulations. - Google Patents

Injectable quinolone formulations. Download PDF

Info

Publication number
OA10697A
OA10697A OA9800082A OA9800082A OA10697A OA 10697 A OA10697 A OA 10697A OA 9800082 A OA9800082 A OA 9800082A OA 9800082 A OA9800082 A OA 9800082A OA 10697 A OA10697 A OA 10697A
Authority
OA
OAPI
Prior art keywords
solution
danofloxacin
added
formulation
pvp
Prior art date
Application number
OA9800082A
Other languages
English (en)
Inventor
Wayne Alan Boettner
Peter Connor Canning
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21735307&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA10697(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of OA10697A publication Critical patent/OA10697A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
OA9800082A 1995-12-21 1998-06-12 Injectable quinolone formulations. OA10697A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US905295P 1995-12-21 1995-12-21

Publications (1)

Publication Number Publication Date
OA10697A true OA10697A (en) 2001-05-04

Family

ID=21735307

Family Applications (1)

Application Number Title Priority Date Filing Date
OA9800082A OA10697A (en) 1995-12-21 1998-06-12 Injectable quinolone formulations.

Country Status (42)

Country Link
US (1) US5811130A (xx)
EP (1) EP0868183B1 (xx)
JP (1) JP3416145B2 (xx)
KR (1) KR100402570B1 (xx)
CN (1) CN1104899C (xx)
AP (1) AP706A (xx)
AR (1) AR005147A1 (xx)
AT (1) ATE212551T1 (xx)
AU (1) AU709474B2 (xx)
BG (1) BG63933B1 (xx)
BR (1) BR9612230A (xx)
CA (1) CA2239352C (xx)
CO (1) CO4480098A1 (xx)
CZ (1) CZ293747B6 (xx)
DE (1) DE69618987T2 (xx)
DK (1) DK0868183T3 (xx)
DZ (1) DZ2146A1 (xx)
EG (1) EG24071A (xx)
ES (1) ES2167609T3 (xx)
GT (1) GT199600098A (xx)
HR (1) HRP960607B1 (xx)
HU (1) HU227918B1 (xx)
IL (1) IL124454A (xx)
IS (1) IS2010B (xx)
MA (1) MA24035A1 (xx)
MX (1) MX9805026A (xx)
MY (1) MY117109A (xx)
NO (1) NO315734B1 (xx)
NZ (2) NZ320545A (xx)
OA (1) OA10697A (xx)
PE (1) PE25798A1 (xx)
PL (1) PL186795B1 (xx)
PT (1) PT868183E (xx)
RS (1) RS49523B (xx)
RU (1) RU2141827C1 (xx)
SI (1) SI0868183T1 (xx)
SK (1) SK284412B6 (xx)
TN (1) TNSN96163A1 (xx)
TW (1) TW449475B (xx)
UA (1) UA56151C2 (xx)
WO (1) WO1997023217A1 (xx)
ZA (1) ZA9610780B (xx)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID21415A (id) * 1997-12-05 1999-06-10 Upjohn Co Senyawa-senyawa antibiotik magnesium quinolon
US6017948A (en) * 1998-10-30 2000-01-25 Supergen, Inc. Water-miscible pharmaceutical compositions
DE19937116A1 (de) 1999-08-06 2001-02-08 Bayer Ag Moxifloxacin Kochsalzformulierung
DE19937115A1 (de) 1999-08-06 2001-02-08 Bayer Ag Wäßrige Arzneimittelformulierung von Moxifloxacin oder Salzen davon
EP1255565A1 (de) * 2000-01-13 2002-11-13 MERCK PATENT GmbH Pharmazeutische zubereitungen enthaltend 2-pyrrolidon als lösungsvermittler
CA2433037C (en) * 2000-12-28 2010-12-21 Takeda Chemical Industries, Ltd. Sustained-release preparation
BR0312111A (pt) * 2002-06-26 2005-03-29 Pharmacia Corp Formulação estável, lìquida, parenteral de parecoxib
RU2007104026A (ru) * 2004-07-02 2008-08-10 Дайити Фармасьютикал Ко., Лтд. (JP) Содержащая хинолон лекарственная композиция
US8524735B2 (en) 2005-05-18 2013-09-03 Mpex Pharmaceuticals, Inc. Aerosolized fluoroquinolones and uses thereof
EP2594272B1 (en) * 2005-05-18 2018-07-11 Horizon Orphan LLC Aerosolized fluoroquinolones and uses thereof
FR2896416B1 (fr) 2006-01-24 2010-08-13 Vetoquinol Composition anti-infectieuse comprenant un compose de type pyrido (3,2,1-ij)-benzoxadiazine
CA2641827A1 (en) * 2006-02-10 2007-08-16 Pari Pharma Gmbh Nebulised antibiotics for inhalation therapy
US20070197548A1 (en) * 2006-02-17 2007-08-23 Murthy Yerramilli V S Fluoroquinolone compositions
DE102006010642A1 (de) * 2006-03-08 2007-09-27 Bayer Healthcare Aktiengesellschaft Arzneimittelformulierungen, enthaltend Fluorchinolone
DE102006010643A1 (de) * 2006-03-08 2007-09-13 Bayer Healthcare Aktiengesellschaft Arzneimittel enthaltend Fluorchinolone
MX2007009796A (es) * 2007-08-14 2009-02-25 Cell Therapy And Technology S Gel conteniendo pirfenidona.
HUE050147T2 (hu) 2008-10-07 2020-11-30 Horizon Orphan Llc Tüdõgyulladás csökkentése levofloxacin belélegzése útján
NO2344129T3 (xx) 2008-10-07 2018-07-21
RU2563809C2 (ru) 2009-09-04 2015-09-20 Мпекс Фармасьютикалс, Инк. Применение левофлоксацина в форме аэрозоля для лечения муковисцидоза
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX346763B (es) 2012-03-28 2017-03-31 Cell Therapy And Tech S A De C V Composición tópica semisólida conteniendo pirfenidona y dialil óxido de disulfuro modificado (odd-m) para eliminar o prevenir el acné.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
EP3305295A4 (en) 2015-06-02 2019-02-20 Kyorin Pharmaceutical Co., Ltd. AQUEOUS MEDICINE
US10617684B2 (en) 2015-06-02 2020-04-14 Kyorin Pharmaceutical Co., Ltd. Aqueous drug
EP3305296A4 (en) 2015-06-02 2019-02-13 Kyorin Pharmaceutical Co., Ltd. AQUEOUS LIQUID FORMULATION
MX2019009572A (es) * 2017-02-13 2019-10-02 Bayer Animal Health Gmbh Composicion liquida que contiene pradofloxacina.
MX366086B (es) 2017-08-15 2019-06-27 Cell Therapy And Tech S A De C V Composicion topica semisolida conteniendo un agente antimicrobiano y pirfenidona para el tratamiento de daños cronicos de la piel.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3517709A1 (de) * 1985-01-05 1986-07-10 Bayer Ag Basische zubereitungen von chinoloncarbonsaeuren
JPS63188626A (ja) * 1987-01-30 1988-08-04 Dainippon Pharmaceut Co Ltd ピリドンカルボン酸の可溶化方法
DE3902079A1 (de) * 1988-04-15 1989-10-26 Bayer Ag I.m. injektionsformen von gyrase-inhibitoren
CA2072366C (en) * 1989-12-29 2002-08-20 Laman A. Al-Razzak Carboxylic acid-metal ion-acid complexes
US5084276A (en) * 1990-01-05 1992-01-28 Abbott Laboratories Quinolone carboxylic acid compositions with polymeric additive to reduce vein irritation
ATE108649T1 (de) * 1990-02-14 1994-08-15 Takeda Chemical Industries Ltd Brausemischung, deren herstellung sowie verwendung.
FR2665635A1 (fr) * 1990-08-10 1992-02-14 Merck Sharp & Dohme Composition pharmaceutique fluide a base d'un complexe metallique et son procede de preparation.
US5082863A (en) * 1990-08-29 1992-01-21 Schering Corporation Pharmaceutical composition of florfenicol
US5235054A (en) * 1992-07-15 1993-08-10 Pfizer Inc. 3-carboxaldehyde substituted quinolines and naphthyridines
JPH0782141A (ja) * 1993-09-17 1995-03-28 Tanabe Seiyaku Co Ltd 動物用注射剤

Also Published As

Publication number Publication date
DE69618987T2 (de) 2002-11-21
CA2239352A1 (en) 1997-07-03
IS4755A (is) 1998-05-25
RU2141827C1 (ru) 1999-11-27
CZ293747B6 (cs) 2004-07-14
HUP9903726A3 (en) 2001-01-29
CZ193098A3 (cs) 1999-05-12
TW449475B (en) 2001-08-11
MX9805026A (es) 1998-09-30
UA56151C2 (uk) 2003-05-15
SK80798A3 (en) 1999-09-10
BG63933B1 (bg) 2003-07-31
MA24035A1 (fr) 1997-07-01
HUP9903726A2 (hu) 2000-04-28
NO982842D0 (no) 1998-06-19
KR100402570B1 (ko) 2003-12-18
ES2167609T3 (es) 2002-05-16
JP3416145B2 (ja) 2003-06-16
US5811130A (en) 1998-09-22
IL124454A (en) 2003-10-31
DK0868183T3 (da) 2002-03-25
EG24071A (en) 2008-05-11
WO1997023217A1 (en) 1997-07-03
BG102542A (en) 1999-06-30
HRP960607A2 (en) 1998-06-30
AP9600898A0 (en) 1997-01-31
SI0868183T1 (en) 2002-04-30
YU69096A (sh) 1999-06-15
KR19990076617A (ko) 1999-10-15
NZ320545A (en) 2000-03-27
CA2239352C (en) 2002-06-04
HU227918B1 (en) 2012-06-28
CN1205636A (zh) 1999-01-20
ZA9610780B (en) 1998-06-22
AP706A (en) 1998-12-04
AU709474B2 (en) 1999-08-26
CO4480098A1 (es) 1997-07-09
EP0868183A1 (en) 1998-10-07
RS49523B (sr) 2006-10-27
DZ2146A1 (fr) 2002-10-23
BR9612230A (pt) 1999-07-13
GT199600098A (es) 1998-06-12
PE25798A1 (es) 1998-05-21
NO982842L (no) 1998-06-19
PL328001A1 (en) 1999-01-04
MY117109A (en) 2004-05-31
PT868183E (pt) 2002-06-28
ATE212551T1 (de) 2002-02-15
SK284412B6 (sk) 2005-03-04
IL124454A0 (en) 1998-12-06
PL186795B1 (pl) 2004-02-27
IS2010B (is) 2005-05-13
NO315734B1 (no) 2003-10-20
DE69618987D1 (de) 2002-03-14
JPH11501331A (ja) 1999-02-02
NZ501160A (en) 2001-10-26
TNSN96163A1 (fr) 2005-03-15
HRP960607B1 (en) 2002-06-30
AR005147A1 (es) 1999-04-14
AU7328996A (en) 1997-07-17
CN1104899C (zh) 2003-04-09
EP0868183B1 (en) 2002-01-30

Similar Documents

Publication Publication Date Title
OA10697A (en) Injectable quinolone formulations.
CA1072012A (en) Stable solutions of oxytetracycline in aqueous 2-pyrrolidone
AU2006271870B2 (en) Solid dosage formulations of narcotic drugs having improved buccal adsorption
CS199527B2 (en) Manufacturing process of the steady antibiotic agent
JP2002529415A (ja) 製薬学的モキシフロキサシン調製物
WO2001036510A3 (en) Use of poly(diallylamine) polymers
CA2011063C (en) Nicardipine pharmaceutical composition for parenteral administration
CA2421410A1 (en) Iron compositions
US4772460A (en) Method of reducing the swelling or pain associated with antibiotics compositions
WO2002102743A3 (de) Deuterierte n- und alpha-substituierte diphenylalkoyxessigsäureaminoalkylester sowie diese verbindungen enthaltende arzneimittel
JP3648531B2 (ja) ファモチジン注射液
CA1135188A (en) Oxytetracycline compositions
PL364801A1 (en) Taste masked compositions
JP2002508330A (ja) ダルホプリスチンおよびキヌプリスチンに基づく医薬組成物ならびに調製
US5674872A (en) Treatment of ovarian cancer
US6110905A (en) Long-acting oxytetracycline composition
JP3330977B2 (ja) ダピプラゾール含有経口投与用固体医薬組成物
AU699436B2 (en) Treatment of non-small cell lung carcinoma
CA2163772A1 (en) Intramuscular and subcutaneous injection solution for animals
EP0337733A2 (en) Single dose intramuscular treatment of chlamydia trachomatis infections
ATE288269T1 (de) Arzneizusammensetzungen und herstellungsverfahren von ergotalkaloidhaltigen arzneizusammensetzungen mit verzögerter wirkstoffabgabe und verbesserter bioverfügbarkeit
HU176305B (hu) Eljárás stabil tetraciklin-készítmények előállítására